StockData
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. (TVRD) stock

TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.01−0.09 (-8.18%)

Close on Nov 17, 2026Market cap $13.47MP/E –Yield 0.00%

Tvardi Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Tvardi Therapeutics's price to sales ratio was 5.2× on Jul 31, 2025, against 3.4× a year earlier. Over the last 5 years it ranged from 2.5× to 95.7×, with a median of 14.8×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jul 31, 20255.2×−4.4
2024Dec 31, 20249.7×+3.9
2023Dec 29, 20235.7×−38.2
2022Dec 30, 202243.9×+30.3
2021Dec 31, 202113.7×−63.7
2020Dec 31, 202077.4×−30.5
2019Dec 31, 2019107.9×−118.6
2016Oct 31, 2016226.5×−65.5
2015Dec 31, 2015292.0×+81.5
2014Dec 31, 2014210.5×–

More Tvardi Therapeutics figures

See a number that looks wrong?